Market Analysis
In-depth Analysis of Avascular Necrosis Market Industry Landscape
People are becoming more aware of avascular necrosis (AVN) because it's becoming more common. In the United States, about 15,000 cases of AVN pop up each year. It's most common in folks between 30 and 50 years old, and it affects males more than females. When kids get it in their femur bone, it's called Legg-Calvé-Perthes syndrome. Taking certain drugs during treatments like chemotherapy, radiation therapy, high-dose steroids, or organ transplants can also lead to osteonecrosis. People with HIV, cancer, gout, Gaucher's disease, and other conditions are also prone to it.
A company presentation by Bone Therapeutics in 2017 mentioned around 170,000 people in the US, Europe, and Japan were dealing with osteonecrosis. More doctors and patients are learning about osteonecrosis, which helps the market for treating it grow. New treatments like stem cell-based therapy and gene therapy are also expected to boost this market.
For osteonecrosis, surgeries are becoming more popular. About 20,000 hip replacement surgeries are done yearly in the US because of osteonecrosis, as reported by the American Academy of Orthopedic Surgeons. While medicines like pain relievers and cholesterol-lowering drugs help control symptoms, they don't cure the condition. That's why surgeries are often needed. Some common surgeries include core decompression to increase blood flow to the bones, joint replacement, bone grafts, and osteotomy to reduce joint stress.
Stanford University is looking into a project to evaluate osteonecrosis before and after decompression surgery using MRI enhanced by ferumoxytol. This helps better detect and track transplanted bone marrow cells. This project is in a phase 4 clinical trial and is expected to make surgical procedures more effective. These kinds of improvements in surgical treatments that work better are likely to push the osteonecrosis treatment market forward.
Avascular necrosis (AVN) is getting more attention because it's becoming more common. In the US alone, there are around 15,000 new cases of AVN every year. It mainly affects people between 30 to 50 years old, and it tends to affect more males than females. When kids have it in their thigh bone, it's called Legg-Calvé-Perthes syndrome. Using certain drugs during treatments like chemotherapy, radiation therapy, high-dose steroids, or organ transplants can also lead to osteonecrosis. People with conditions like HIV, cancer, gout, Gaucher's disease, and others are also at risk.
A presentation by Bone Therapeutics in 2017 mentioned that about 170,000 people in the US, Europe, and Japan were dealing with osteonecrosis. More doctors and patients are learning about osteonecrosis, which helps the market for treating it grow. New treatments like using stem cells or gene therapy are expected to make this market even bigger.
Surgeries for osteonecrosis are getting more popular. The American Academy of Orthopedic Surgeons says there are about 20,000 hip replacement surgeries every year in the US because of osteonecrosis. While medicines like pain relievers and drugs that lower cholesterol can help control the symptoms, they can't cure the condition. That's why surgeries are often needed. Some common surgeries include doing a core decompression to increase blood flow to the bones, replacing the joint, bone grafts, and osteotomy to reduce stress on the joint.
Stanford University is working on a project to check osteonecrosis before and after decompression surgery using a special kind of MRI that's enhanced by ferumoxytol. This helps find and track transplanted bone marrow cells better. This project is in a phase 4 clinical trial and is expected to make surgical procedures work even better. When surgical treatments improve like this, it's likely to help the market for osteonecrosis treatments to grow even more.
Leave a Comment